Conditions and Treatments
Ratings and Reviews
213 Ratings 27 Comments
|CP concern for questions/worries||4.9|
|CP efforts to include in decisions||4.8|
|CP explanations of prob/condition||4.9|
|CP spoke using clear language||4.9|
|Friendliness/courtesy of CP||4.8|
|Likelihood of recommending CP||4.9|
|Patients' confidence in CP||4.9|
|Time CP spent with patient||4.8|
|Wait time at clinic||4.5|
The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Experience Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good.
- BA, Wake Forest University, 1974
- MD, Wake Forest School of Medicine, 1978
- Obstetrics & Gynecology, North Carolina Baptist Hospital, 1979
- Obstetrics & Gynecology, North Carolina Baptist Hospital, 1982
- Mayo Clinic, 1989
- American Board of Obstetrics and Gynecology, Gynecologic Oncology
- American Board of Obstetrics and Gynecology, Obstetrics and Gynecology
- American Board of Obstetrics and Gynecology, Female Pelvic Medicine and Reconstructive Surgery
- Section Head, Gynecologic Oncology
- Professor, Gynecologic Oncology
- Professor, Urology
Wake Forest Baptist accepts most major health insurance plans for hospital, physician and clinic services and participates in Medicare and Medicaid government programs. For more information, visit Billing and Insurance.
This chart is a list of the most common health insurance plans we accept. This list is subject to change. Please check your individual plan to confirm their participation and the coverage allowed.
Due to the different physician groups and hospitals within the Wake Forest Baptist system, physician services and hospital services are billed separately. Please remember that health insurance coverage varies, so some services may not be covered.
If you don’t see your plan or you have questions, please call our Customer Service Center at 877-938-7497. We will do our best to work with you and your plan.
WFUHS - Wake Forest University Health Sciences (physician services)
NCBH - North Carolina Baptist Hospital
Davie - Davie Medical Center
LMC - Lexington Medical Center
CHC - Cornerstone Healthcare
Wilkes - Wilkes Regional Medical Center
N/A - Not applicable to services provided at facility and/or CHC
NC - Not contracted, very low to no volume for facility and/or CHC
|WAKE FOREST BAPTIST HEALTH|
|MANAGED CARE CONTRACTS - December 2017|
|AETNA (PPO & HMO)||X||X||X||X||X||X|
|BCBSNC (PPO & HMO)||X||X||X||X||X||X|
|CAROLINA BEHAVIORAL HEALTH||X||X||N/A||N/A||X||N/A|
|CIGNA BEHAVIORAL HEALTH||X||N/A||N/A||N/A||N/A|
|CIGNA HEALTHSPRING MEDICARE ADVANTAGE||X||X||X||X||X||N/A|
|CIGNA LIFESOURCE (TRANSPLANTS)||X||X||N/A||N/A||N/A||N/A|
|CRESCENT PPO (ASHEVILLE)||X||X||NC||NC||NC||NC|
|FIRST HEALTH (COVENTRY)||X||X||X||X||X||X|
|FIRSTCAROLINACARE (PINEHURST, NC)||NC||X||NC||NC||NC||NC|
|GATEWAY HEALTH ALLIANCE (VIRGINIA)||X||X||NC||NC||NC||NC|
|GOLDEN RULE INS (UNITED)||X||X||X||X||X||X|
|HEALTHGRAM (formerly PRIMARY PHYSICIAN CARE)||X||X||NC||X||NC||NC|
|HUMANA MEDICARE ADVANTAGE||X||X||X||X||X||X|
|LIBERTY ADVANTAGE (MEDICARE ADVANTAGE)||X||X||N/A||N/A||N/A||N/A|
|MAGELLAN (BEHAVIORAL HEALTH)||X||X||N/A||N/A||X||N/A|
|OPTUMHEALTH (TRANSPLANTS - APPLICABLE TO NCBH/WFUHS ONLY)||X||X||N/A||N/A||N/A||N/A|
|PREFERRED CARE OF VA INC||X||X||NC||NC||NC||NC|
|SOUTHERN HEALTH SVCS (COVENTRY-PPO ONLY)||X||X||X||NC||X||NC|
|TWIN COUNTY (VIRGINIA)||X||X||NC||NC||NC||NC|
|UNITED BEHAVIORAL HEALTH||X||X||N/A||N/A||X||N/A|
|UNITED BEHAVIORAL HEALTH INTENSIVE OUTPATIENT PROGRAM (WFUHS ONLY)||X||N/A||N/A||N/A||N/A||N/A|
|UNITED HEALTHCARE MEDICARE||X||X||X||X||X||X|
|LEXINGTON ONLY - Contracts specific to support Lexington employer groups, low volume|
|NATIONAL PROVIDER NETWORK/MEDICAL RESOURCES|
|CHC ONLY - Contracts specific to support CHC|
|AETNA BEHAVIORAL HEALTH|
CIGNA BEHAVIORAL HEALTH (limited providers)
|THN - TRIAD HEALTH NETWORK MA Plans only (Humana Medicare and Healthteam Advantage)|
|N/A = not applicable to services provided at facility and/or CHC|
|NC = Not Contracted, very low to no volume for facility and/or CHC|
|WFUHS - Wake Forest University Health Sciences (professional services)|
|NCBH - North Carolina Baptist Hospital|
|DAVIE - Davie Medical Center|
|LMC - Lexington Medical Center|
|CHC - Cornerstone Healthcare|
|Wilkes - Wilkes Regional Medical Center|
- Serum Calcium and Serum Albumin Are Biomarkers That Can Discriminate Malignant from Benign Pelvic Masses. Kelly MG, Winkler SS, Lentz SS, Berliner SH, Swain MF, Skinner HG, Schwartz GG. Cancer Epidemiol. Biomarkers Prev. 2015 Oct; 24(10):1593-8.
- Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study. Berek JS, Edwards RP, Parker LP, DeMars LR, Herzog TJ, Lentz SS, Morris RT, Akerley WL, Holloway RW, Method MW, Plaxe SC, Walker JL, Friccius-Quecke H, Krasner CN. Int. J. Gynecol. Cancer. 2014 Nov; 24(9):1583-9.
- Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173. Coleman RL, Ali S, Levenback CF, Gold MA, Fowler JM, Judson PL, Bell MC, De Geest K, Spirtos NM, Potkul RK, Leitao MM, Bakkum-Gamez JN, Rossi EC, Lentz SS, Burke JJ, Van Le L, Trimble CL. Gynecol. Oncol. 2013 Feb; 128(2):155-9.
- Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study. Levenback CF, Ali S, Coleman RL, Gold MA, Fowler JM, Judson PL, Bell MC, De Geest K, Spirtos NM, Potkul RK, Leitao MM, Bakkum-Gamez JN, Rossi EC, Lentz SS, Burke JJ, Van Le L, Trimble CL. J. Clin. Oncol. 2012 Nov; 30(31):3786-91.
- A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Coleman RL, Brady WE, McMeekin DS, Rose PG, Soper JT, Lentz SS, Hoffman JS, Shahin MS. Gynecol. Oncol. 2011 Jul; 122(1):111-5.
- Study to see how chemotherapy and radiation effect your cancer of the vulva
- Treatment for patients with a stromal tumor of the ovary
- The Effects of Atezolizumab vs. Placebo in combination with Bevacizumab and Standard-of-Care Therapy for patients with new Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer